GlobeNewswire Inc.··NaAligos Scores $25M Upfront in China Deal for Hepatitis B Drug
Aligos Therapeutics licenses pevifoscorvir to Xiamen Amoytop for Greater China development, receiving $25M upfront and up to $420M in milestones.
ALGSclinical developmentpevifoscorvir sodium